Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $72.00

Posted by Francis Steltz on Aug 1st, 2026

Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its price objective hoisted by Wells Fargo & Company from $48.00 to $72.00 in a report released on Wednesday morning,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

CLDX has been the topic of several other reports. UBS Group increased their target price on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Guggenheim boosted their price target on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Cantor Fitzgerald dropped their price objective on Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating for the company in a research note on Wednesday, July 22nd. Canaccord Genuity Group reduced their target price on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $42.00 target price on shares of Celldex Therapeutics in a research note on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $54.62.

Get Our Latest Stock Report on CLDX

Celldex Therapeutics Trading Down 1.1%

Celldex Therapeutics stock opened at $38.06 on Wednesday. The firm has a 50 day simple moving average of $34.30 and a 200 day simple moving average of $31.03. Celldex Therapeutics has a 1-year low of $19.72 and a 1-year high of $40.30. The firm has a market capitalization of $2.99 billion, a price-to-earnings ratio of -8.93 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.80 million. On average, equities research analysts forecast that Celldex Therapeutics will post -4.36 EPS for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after acquiring an additional 680 shares during the last quarter. Millennium Management LLC raised its holdings in Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock worth $7,259,000 after acquiring an additional 306,330 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Celldex Therapeutics by 12.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock valued at $2,383,000 after acquiring an additional 14,979 shares in the last quarter. Russell Investments Group Ltd. lifted its position in Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 501 shares in the last quarter. Finally, Hsbc Holdings PLC purchased a new stake in Celldex Therapeutics during the 2nd quarter valued at $347,000.

Celldex Therapeutics Company Profile

(Get Free Report)

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.